These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 16465429)

  • 1. Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours.
    Persson MI; Gedda L; Jensen HJ; Lundqvist H; Malmström PU; Tolmachev V
    Oncol Rep; 2006 Mar; 15(3):673-80. PubMed ID: 16465429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma.
    Nestor M; Persson M; van Dongen GA; Jensen HJ; Lundqvist H; Anniko M; Tolmachev V
    Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1296-304. PubMed ID: 16028065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate.
    Lindegren S; Frost S; Bäck T; Haglund E; Elgqvist J; Jensen H
    J Nucl Med; 2008 Sep; 49(9):1537-45. PubMed ID: 18703591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.
    Dekempeneer Y; Bäck T; Aneheim E; Jensen H; Puttemans J; Xavier C; Keyaerts M; Palm S; Albertsson P; Lahoutte T; Caveliers V; Lindegren S; D'Huyvetter M
    Mol Pharm; 2019 Aug; 16(8):3524-3533. PubMed ID: 31268724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the potential of 188Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment.
    Luo TY; Tang IC; Wu YL; Hsu KL; Liu SW; Kung HC; Lai PS; Lin WJ
    Nucl Med Biol; 2009 Jan; 36(1):81-8. PubMed ID: 19181272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction.
    Akabani G; Carlin S; Welsh P; Zalutsky MR
    Nucl Med Biol; 2006 Apr; 33(3):333-47. PubMed ID: 16631082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
    Chen KT; Lee TW; Lo JM
    Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative tissue distribution in mice of the alpha-emitter 211At and 131I as labels of a monoclonal antibody and F(ab')2 fragment.
    Garg PK; Harrison CL; Zalutsky MR
    Cancer Res; 1990 Jun; 50(12):3514-20. PubMed ID: 2340501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells.
    Kim WE; Serrero G
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4192-9. PubMed ID: 16857791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cetuximab in combination with alpha-radioimmunotherapy in cultured squamous cell carcinomas.
    Nestor M; Sundström M; Anniko M; Tolmachev V
    Nucl Med Biol; 2011 Jan; 38(1):103-12. PubMed ID: 21220133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
    Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab enhances the anti-proliferative effect of trastuzumab in ERBB2 over-expressing breast cancer cells--preliminary study.
    Uberall I; Krízová K; Steigerová J
    Klin Onkol; 2011; 24(5):356-60. PubMed ID: 22070017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization.
    Li B; Meng Y; Zheng L; Zhang X; Tong Q; Tan W; Hu S; Li H; Chen Y; Song J; Zhang G; Zhao L; Zhang D; Hou S; Qian W; Guo Y
    Cancer Res; 2013 Nov; 73(21):6471-83. PubMed ID: 24046294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer.
    Pályi-Krekk Z; Barok M; Isola J; Tammi M; Szöllosi J; Nagy P
    Eur J Cancer; 2007 Nov; 43(16):2423-33. PubMed ID: 17911008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab.
    Boskovitz A; McLendon RE; Okamura T; Sampson JH; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2009 Aug; 36(6):659-69. PubMed ID: 19647172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice.
    Palm S; Bäck T; Claesson I; Danielsson A; Elgqvist J; Frost S; Hultborn R; Jensen H; Lindegren S; Jacobsson L
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):572-9. PubMed ID: 17869670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of HER2-expressing breast cancer and ovarian cancer cells with alpha particle-emitting 227Th-trastuzumab.
    Heyerdahl H; Krogh C; Borrebæk J; Larsen Å; Dahle J
    Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):563-70. PubMed ID: 21195878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioimmunotherapy with an
    Takashima H; Koga Y; Manabe S; Ohnuki K; Tsumura R; Anzai T; Iwata N; Wang Y; Yokokita T; Komori Y; Mori D; Usuda S; Haba H; Fujii H; Matsumura Y; Yasunaga M
    Cancer Sci; 2021 May; 112(5):1975-1986. PubMed ID: 33606344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reagents for astatination of biomolecules: comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nido-carboranyl compounds.
    Wilbur DS; Chyan MK; Hamlin DK; Kegley BB; Risler R; Pathare PM; Quinn J; Vessella RL; Foulon C; Zalutsky M; Wedge TJ; Hawthorne MF
    Bioconjug Chem; 2004; 15(1):203-23. PubMed ID: 14733601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions.
    Bernard-Marty C; Lebrun F; Awada A; Piccart MJ
    Drugs; 2006; 66(12):1577-91. PubMed ID: 16956305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.